Trial Profile
Evaluation of a real-world experience of a bridging protocol using cangrelor for patients referred to relevant bleeding risk surgery requiring withdrawal of dual antiplatelet therapy (DAPT)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2020
Price :
$35
*
At a glance
- Drugs Cangrelor (Primary)
- Indications Coronary thrombosis
- Focus Adverse reactions
- 31 Oct 2018 New trial record
- 25 Sep 2018 Results presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics